Key Segmentation
By Type
-
Peptides
-
Oligonucleotides
-
Conjugates
By Application
-
Pharmaceuticals
-
Diagnostics
-
Cosmetics
By Synthesis Route
-
Solid-phase Synthesis
-
Solution-phase Synthesis
-
Automated Synthesis
By Scale
-
Preclinical
-
Clinical
-
Commercial
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The peptide and oligonucleotide CDMO market was valued at USD 3.34 Billion in 2025.
The major growth factors include rising outsourcing, increasing peptide therapeutics demand, expanding oligonucleotide use in precision medicine, growing biologics pipelines, automated synthesis adoption, and focus on cost efficient scalable manufacturing solutions.
The Peptides segment dominated the market in 2025 due to strong therapeutic adoption, oncology use, established processes, and large scale outsourcing.
North America dominated the peptide and oligonucleotide CDMO market in 2025 due to strong outsourcing demand and advanced R&D infrastructure.